

Prescribing proton pump inhibitors in patients with acute coronary syndrome on dual anti platelet therapy - a quality improvement project

Julia Tua, Julian Delicata, Maria Farrugia, Maryanne Caruana

AIM

The European Society of Cardiology (ESC) now recommend the use of proton pump inhibitors (PPIs) in all patients on dual anti-platelet therapy (DAPT). Our aim is to improve awareness of the new 2017 ESC recommendations of prescribing PPIs in all patients on DAPT by presenting the guideline at a departmental meeting

Methodology

During the first cycle of the audit data was collected from January till March 2018. The data collected included patients who were discharged from cardiology wards by the cardiology team on DAPT after an ACS. Patients on warfarin, dipyridamole or prasugrel were not included. Treatment on discharge was reviewed on Electronic Case Summaries (ECS). In July 2018 the results of the audit, and the guidelines, were discussed during a 10 minute departmental meeting with doctors and nurses working in cardiology. A re-audit was then performed in September 2018. Chi square test was used to calculate the significant change between the 1st and 2nd cycle of the audit.

Results

In the first cycle of the audit from January till March 2018, 36% of the total 183 (n=65) were discharged home on a PPI. In the second cycle of the audit in September 2018, of the total 61 patients, 90% (n=55) were discharged home on a PPI. There was a significant increase in prescription of PPIs in the 2nd cycle of the audit ($p < 0.001$)

Discussion

Our quality improvement project was low cost and has shown that a discussion amongst team members can effectively alter clinical practice.

Conclusion

PPI prescription improved drastically after a short 10 minute presentation of the guidelines during a departmental meeting.